PTPN2 and neoplasm: Enhanced efficacy of PTPN2-deficient CAR-T cells was associated with elevated Lck and STAT5-dependent cytotoxic T lymphocyte (CTL) function and superior STAT5-dependent and CXC chemokine receptor 3 (CXCR3)-mediated homing of CAR-T cells to tumours [27].